Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.31 |
| ▸ | FOS | P01100 | 1/20 | 0.31 |
| ▸ | JUN | P05412 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26205647 | 0.89 | GRM2 (0.32) | GRM2AAK1PTGER1LMNAKDM4E | |
| SCHEMBL26205638 | 0.82 | AAK1 (0.39) | AAK1LMNA | |
| SCHEMBL26205632 | 0.82 | SMN1; SMN2 (0.36) | GRM2LMNAKDM4ECYP1A2SMN1; SMN2 | |
| SCHEMBL26205643 | 0.80 | GPR88 (0.35) | LMNAKDM4ECYP1A2GPR88 | |
| SCHEMBL30168979 | 0.78 | AAK1 (0.53) | AAK1PTGER1 | |
| SCHEMBL22526343 | 0.78 | AAK1 (0.53) | AAK1PTGER1 | |
| SCHEMBL26205646 | 0.78 | PTGER1 (0.33) | PTGER1KDM4ECYP1A2SMN1; SMN2 | |
| SCHEMBL26206406 | 0.77 | FOS (0.35) | PRSS1TMPRSS15FOSJUN | |
| SCHEMBL26205653 | 0.77 | PKM (0.33) | — | |
| SCHEMBL26205652 | 0.76 | SMN1; SMN2 (0.32) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | GRM2 4273/4885AAK1 2860/4885PTGER1 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.